JTR  Vol.7 No.1 , March 2019
Multidrug-Resistant Tuberculosis in the Democratic Republic of Congo: Analysis of Continuous Surveillance Data from 2007 to 2016
Abstract: Background: For countries with limited resources such as the Democratic Republic of the Congo (DRC), the diagnosis of Multidrug-resistant tuberculosis (MDR-TB) is still insufficient. The MDR-TB identification is done primarily among at-risk groups. The knowledge of the true extent of the MDR-TB remains a major challenge. This study tries to determine the proportion of MDR-TB in each group of presumptive MDR-TB patients and to identify some associated factors. Methods: This is an analysis of the DRC surveillance between 2007 and 2016. The proportions were expressed in Percentage. The logistic regression permits to identify the associated factors with the RR-/MDR-TB with adjusted Odds-ratio and 95% CI. Significance defined as p ≤ 0.05. Results: Overall, 83% (5407/6512) of the MDR-TB presumptive cases had each a TB test. 86.5% (4676/5407) had each a culture and drug sensitive testing (DST) on solid medium, and 24.3% (1312/5407) had performed an Xpert MTB/RIF test. The proportion of those with at least one first-line drug resistance was 59.3% [95% CI 57.2 - 61.4] among which 50.1%, [95% CI 47.9 - 52.3] for the isoniazid, 45.6% [95% CI 43.4 - 47.8] for the rifampicin, 49.9% [95% CI 47.8 - 52.1] for ethambutol and 35.8% [95% CI 33.7 - 37.9] for streptomycin. The confirmation of MDR-TB was 42.8% [95% CI 38.4 - 47.8]. Combining both tests, the proportion of RR-/MDR-TB was 49.6% [95% CI 47.9 - 51.4] for all presumptives. This proportion was 60.0% for failures, 40.7% for relapses and 34.7% for defaulters. Associated factors with the diagnosis of MDR-TB were: aged less than 35 years; prior treatment failure; defaulters; the delay between the collection of sputum and the test completion. Conclusion: The proportion of RR-/MDR-TB among the presumptives has been higher than those estimated generally. The National tuberculosis programme (NTP) should improve patient follow-up to reduce TB treatment failures and defaulting. Moreover, while increasing the use of molecular tests, they should reduce sample delivery times when they use culture and DST concomitantly.
Cite this paper: Bisuta-Fueza, S., Kayembe-Ntumba, J.M., Kabedi-Bajani, M.-J., Sabwe, P.M., Tuma, H.S.-N., Simelo, J.-P., Sumaili-Kiswaya, E., Ditekemena-Dinanga, J. and Kayembe-Kalambayi, P. (2019) Multidrug-Resistant Tuberculosis in the Democratic Republic of Congo: Analysis of Continuous Surveillance Data from 2007 to 2016. Journal of Tuberculosis Research, 7, 25-44. doi: 10.4236/jtr.2019.71004.

[1]   World Health Organization (2008) Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Emergency Update. Geneva.

[2]   Johnson, R., Streicher, E.M., Louw, G.E., Warren, R.M., Helden, P.D. and Victor, T.C. (2005) Drug Resistance in Mycobacterium Tuberculosis. Current Issues in Molecular Biology, 8, 97.

[3]   Steingart, K.P., Sohn, H., Schiller, I., Kloda, L.A., Boehme, C.C., Pai, M. and Dendukuri, N. (2013) Xpert® MTB/RIF Assay for Pulmonary Tuberculosis and Rifampicin Resistance in Adults. Cochrane Database of Systematic Reviews, 1, CD009593.

[4]   World Health Organization (2017) Guidelines for the Treatment of Drug Susceptible Tuberculosis and Patient Care. 2017 Update, Geneva, 1-73.

[5]   World Health Organization (2017) Global Tuberculosis Report 2017. GTB, Geneva, WHO/HTM/TB/2017.

[6]   Dean, A. and Zignol, M. (2015) Guidelines for Surveillance of Drug Resistance in Tuberculosis. 5th Edition, WHO, Geneva, 1-73.

[7]   Programme National de lutte contre la Tuberculose (2016) Guide technique de prise en charge de la Tuberculose multi résistance. Kinshasa. Ministère de Santé-RDC, 10-154.

[8]   Van Deun, A., Hamid Salim, A., Rigouts, L., Rahman, M., Fissette, K. and Portaels, F. (2001) Evaluation de la lutte antituberculeuse par des tests de sensibilité périodiques ou en routine dans les cas traités antérieurement. International Journal of Tuberculosis and Lung Disease, 5, 329-338.

[9]   Nkhoma, W.A.C. (2012) Multidrug-Resistant and Extensively-Resistant Tubercusosis in the African Region. The African Health Monitor Diseases Control. Communicable Diseases Control, 15, 22-29.

[10]   World Health Organization (2018) Global Tuberculosis Report 2018. Geneva.

[11]   Bisuta-Fueza, S., Kayembe-Kalambayi, P., Kabedi-Bajani, M., Situakibanza-Nani, T.H. and Kayembe-Ntumba, J.M. (2018) Tendances de la tuberculose pulmonaire bactériologiquement confirmée et issues thérapeutiques en République Démocratique du Congo: 2007-2017. Annals of African Medicine, 11, e2489-e2496.

[12]   World Health Organization (2014) Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO, Geneva, WHO/HTM/TB/2014.11.

[13]   Zignol, M., Dean, A.S., Falzon, D., Gemert, W., Wright, A., Van Deun, A., Portaels, F., Laszlo, A., et al. (2016) Twenty Years of Global Surveillance of Antituberculosis-Drug-Resistance. The New England Journal of Medicine, 375, 1081-1089.

[14]   Pavlenko, E., Barbova, A., Hovhannesyan, A., Tsenilova, Z., Slavuckij, A., Shcherbak-Verlan, et al. (2018) Alarming Levels of Multidrug-Resistant Tuberculosis in Ukraine: Results from the First National Survey. International Journal of Tuberculosis and Lung Disease, 22, 197-205.

[15]   Programme National de lutte contre la Tuberculose (2016) Guide technique de prise en charge de la Tuberculose Programme Anti Tuberculeux intégré aux soins de Santé de base 5ème édition. Kinshasa, Ministère de la Santé.

[16]   Misombo, A., Nguefack-Tsague, G., Kalla, G.M., Afane Ze, E., Kimpanga, D., Panda, T., Ilunga Kebela, Bisuta Fueza, S., Magazani, N. and Mbopi-Kéou, F.-X. (2016) Facteurs de risque de la tuberculose multi-résistante dans la ville de Kinshasa en République Démocratique du Congo. Pan Afrincan Medical Journal, 23, 1-11.

[17]   Kayembe, J.M., Lukiana, T. and Bisuta, F.S. (2004) Tuberculose Chronique: Profil épidémiologique aux Cliniques Universitaires de Kinshasa (2000-2003). International Journal of Tuberculosis and Lung Disease, 11, S80.

[18]   Kabedi, M.J., Kashongwe, M., Kayembe, J.M., Mumba Ngoyi, D., Mampas, I.P., Mbaya, P., Fissette, K., Verheagen, J., Porteals, F. and Muyembe, T.J. (2007) Résistance primaire de Mycobacterium tuberculosis aux antituberculeux à Kinshasa, République Démocratique du Congo. Bulletin de la Société de Pathologie Exotique, 100, 275-276.

[19]   World Health Organization (2012) Biosafety of Tuberculosis Laboratory. Geneva.

[20]   World Health Organization (2011) Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva.

[21]   World Health Organization (2014) Définitions et cadre de notification pour la Tuberculose-Révision 2013. Genève.

[22]   Caminero, J.A. (2010) Multidrug-Resistant Tuberculosis: Epidemiology, Risk Factors and Case Finding. International Journal of Tuberculosis and Lung Disease, 14, 382-390.

[23]   World Health Organization (2016) Global Tuberculosis Report 2016. Geneva.

[24]   ONUSIDA. Rapport ONUSIDA 2016. Geneva.

[25]   World Health Organization (2015) Collaborative HIV/TB Implementing Strategy. Geneva.

[26]   Global Laboratory Initiative-Stop Tb Department (2017) Model Tuberculosis Diagnostic Algorithms. World Health Organization, Geneva.

[27]   Kai, B. (2007) Barrier to Reaching the Target for Tuberculosis Control: Multidrug Resistance Tuberculosis. Bulletin of World Health Organ, 85, 387-394.

[28]   Nourzad, S., Jenkins, H.E., Milstein, M. and Mitnick, C.D. (2017) Estimating the Global Burden of Multidrug-Resistant Tuberculosis among Prevalent Cases of Tuberculosis. International Journal of Tuberculosis and Lung Disease, 21, 6-11.

[29]   Velásquez, G., Yagui, M., Cegielski, P., Asencios, L., Bayona, J., Cesar, B., Hector Yale, G., Suárez, C., Atwood, S., Contreras, C. and Shin, S. (2011) Targeted Drug-Resistance Testing Strategy for Multidrug-Resistant Tuberculosis Detection, Lima, Peru, 2005-2008. Emerging Infectious Diseases, 17, 3.

[30]   Assefa, D., Seyoum, B. and Oljira, L. (2017) Determinants of Multidrug-Resistant Tuberculosis in Addis Ababa, Ethiopia. Infection and Drug Resistance. Open Access, 10, 209-213.

[31]   World Health Organization (2014) Xpert MTB/RIF Implementation Manual-Technical and Operational “How-to Practical Considerations”. WHO, Geneva.

[32]   Falzon, D., Mirzayev, F., Wares, F., Baena, I., Zignol, M., Linh, N., Weyer, K., Jaramillo, E., Floyd, K. and Raviglione, M. (2015) Multidrug-Resistant Tuberculosis around the World: What Progress Has Been Made? European Respiratory Society, 45, 150-160.

[33]   Kabedi, B., Kayembe Ntumba, J.M., Kashongwe, M.Z., Bisuta Fueza, S., Mbaya Kalumba, P., Taba Kalulu, M. and Muyembe, T.J. (2017) GEN-XPERT® MTB/RIF Contribution in the Diagnosis of Pulmonary Tuberculosis with a Negative Bacilloscopy in Kinshasa (DRC). International Journal of Medical Reviews, 3, 160-163.

[34]   Kamal, M.M., Hossain, M.A., Sultana, S., Begum, V., Haque, N., Ahmed, M.J., Rahman, M.A., Hyder, M.A., Hossain, Md.S., Rahman, M., Chowdhury, R.A., Aung, K.J.M., Islam, Md.A., Hasan, M.R. and Van Deun, A. (2015) Résistance aux médicaments antituberculeux au Bangladesh: Réflexions à partir de la première enquête nationale. International Journal of Tuberculosis and Lung Disease, 19, 151-156.

[35]   Weldegebreal, S. and Mebrahtu, T. (2017) Anti-Tuberculosis Drug Resistance in Ethiopia: Systematic Review. International Journal of Tuberculosis and Lung Disease, 21, 18-22.

[36]   McGrath, M., Gey van P., N.C., van Helden, P.D., Warren, R.M. and Warner, D.F. (2014) Mutation Rate and the Emergence of Drug Resistance in Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 69, 292-302.

[37]   Zignol, M., Van Gemert, W., Falzon, D., Sismanidis, C., Glaziou, P., Floyd, Ka. and Raviglione, M. (2012) Surveillance of Anti-Tuberculosis Drug Resistance in the World: An Updated Analysis, 2007-2010. Bulletin of the World Health Organization, 90, 111-119.

[38]   Bisuta, F.S., Kashongwe, M.Z., Kayembe, N.J.M., Mbaki, N.C., Bahati, R.E., Simelo, K.J.P., Muyembe, T.J.J. and Bakaswa, N.G. (2006) Prise en charge de la tuberculose à bacilles multirésistants avec les antituberculeux de seconde ligne à Kinshasa: Résultats préliminaires. Congo Médical, 4, 504-512.

[39]   Kritski, A.L., Rodrigues de Jesus, L., Andrade, M.K., Werneck-Barroso, E., Vieira, M.A., Haffner, A. and Riley, L.W. (1997) Retreatment Tuberculosis Cases. Factors Associated with Drug Resistance and Adverse Outcomes. Chest, 111, 1162-1167.

[40]   Lukoye, D., Ssengooba, W., Musisi, K.W., Kasule, G., Cobelens, F.G., Joloba, M. and Gomez, G.B. (2015) Variation and Risk Factors of Drug Resistant Tuberculosis in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. BMC Public Health, 15, 1-13.

[41]   Espinal, M.A., Kim, S.J., Suarez, P.G., Kam, K.M., Khomenko, A.G., Migliori, G.B., Baéz, J., Kochi, A., Dye, C. and Raviglione, M. (2000) Standard Short Course Chemotherapy for Drug-Resistance Tuberculosis. Treatment Outcomes in 6 Countries. Journal of American Medical Association, 283, 2537-2545.

[42]   Sberbaro, J. (2004) How Frequently Do Patients Stop Taking Treatment Prematurely? In: Toman’s Tuberculosis Case Finding, Treatment and Monitoring, Questions and Answer, 2nd Edition, Geneva, 181-182.

[43]   Banu, S., Rahman, M.T., Ahmed, S., Khatun, R., Ferdous, S.S., Hosen, B., Rahman, M.M., Ahmed, T., Cavanaugh, J.S. and Heffelfinger, J.D. (2017) Multidrug-Resistant Tuberculosis in Bangladesh: Results from a Sentinel Surveillance System. International Journal of Tuberculosis and Lung Disease, 21, 12-17.